Madrigal Pharmaceuticals, Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

MGL-3196 · Cardiovascular
MGL-3196 is a thyroid hormone receptor beta (THR-β) selective agonist that activates THR-β to reduce cholesterol and triglycerides while minimizing systemic thyroid hormone effects.

Phase 1 pipeline

VIA-3196

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: